Eli Lilly's GLP-1 pill Foundayo helped alleviate sleep apnea in studies
Reported bySTAT News ↗·Sourced by Goodlede
In a one-year trial, patients taking Foundayo saw a reduction of 17.8 breathing events per hour on the apnea-hypopnea index, compared with 4.5 events in the placebo group, and 28% of treated patients achieved remission or mild disease versus 13% on placebo.
This is a late-stage study result, not yet in routine use. The injectable version Zepbound appears more effective.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at STAT News
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede